IND Safety Analysis Requires Broader Unblinding Of Reports, US FDA Advises
This article was originally published in SRA
A draft guidance from the US Food and Drug Administration is recommending that pharmaceutical sponsors develop safety assessment committees that would review safety information in a drug development program and determine what information must be reported in an investigational new drug (IND) safety report.
You may also be interested in...
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.